Pharmacology and therapeutics: Review Tamoxifen vs. non-tamoxifen treatment for advanced melanoma: a meta-analysis

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Systemic treatments for metastatic cutaneous melanoma

  2012cited by this paper
• New TNM melanoma staging system: linking biology and natural history to clinical outcomes.

  2003cited by this paper
• Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention.

  2003cited by this paper
• Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials.

  2003cited by this paper
• Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy.

  2003cited by this paper
• Use of tamoxifen in the treatment of malignant melanoma

  2003cited by this paper
• Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.

  2001cited by this paper
• Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients

  2001cited by this paper
• Tamoxifen for the Reduction in the Incidence of Breast Cancer in Women at High Risk for Breast Cancer a

  2001cited by this paper
• Systemic treatments for metastatic cutaneous melanoma.

  2000cited by this paper
• A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma

  2000cited by this paper
• Improving the Quality of Reports of Meta-Analyses of Randomised Controlled Trials: The QUOROM Statement

  1999cited by this paper
• Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.

  1999cited by this paper
• A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma

  1999cited by this paper
• High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable nonsmall cell lung carcinoma

  1999cited by this paper
• Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma.

  1999cited by this paper
• A Phase I and pharmacokinetic study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma

  1997cited by this paper
• Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma.

  1997cited by this paper
• The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921).

  1996cited by this paper
• Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.

  1996cited by this paper
• Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up

  1995cited by this paper
• Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas.

  1995cited by this paper
• Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma a biologically important observation

  1993cited by this paper
• Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen.

  1992cited by this paper
• High‐dose cisplatin with dacarbazine and tamoxifen in the treatment of metastatic melanoma

  1991cited by this paper
• Effect of 17 beta-estradiol on the growth of estrogen receptor-positive human melanoma in vitro and in athymic mice.

  1988cited by this paper
• In vitro stimulation of human NK activity by an estrogen antagonist (tamoxifen)

  1984cited by this paper

• Melanoma-specific risk associated with Hormone Replacement Therapy and Fertility treatments: A narrative review and a clinical guide

  2025cites this paper
• Evaluation of reported claims of sex-based differences in treatment effects across meta-analyses: a meta-research study

  2024cites this paper
• Melanoma and sex hormones: Pathogenesis, progressive disease and response to treatments

  2024influential citation
• Reprogramming of endothelial gene expression by tamoxifen inhibits angiogenesis and ERα-negative tumor growth

  2024cites this paper
• Protective Effects of Trans-Ferulic acid on Tamoxifen Induced Heptatic and Renal Oxidative Stress in Male Wister Albino Rat

  2023cites this paper
• Metabolic modelling-based in silico drug target prediction identifies six novel repurposable drugs for melanoma

  2023cites this paper
• AL16ALA-SOD2 polymorphism predicts recurrence risk of breast cancer in patients treated with adjuvant tamoxifen

  2023cites this paper
• Female melanoma and estrogen receptors expression: an immunohistochemical pilot study

  2022cites this paper
• Potential immunological effects of gender-affirming hormone therapy in transgender people – an unexplored area of research

  2022cites this paper
• Melanoma in pregnancy: Diagnosis and management in early-stage and advanced disease.

  2022cites this paper
• G Protein-Coupled Estrogen Receptor in Cancer and Stromal Cells: Functions and Novel Therapeutic Perspectives

  2021cites this paper
• Melanoma in Pregnancy

  2021cites this paper
• Is Uveal Melanoma a Hormonally Sensitive Cancer? A Review of the Impact of Sex Hormones and Pregnancy on Uveal Melanoma

  2021cites this paper
• Tamoxifen is a candidate first‐in‐class inhibitor of acid ceramidase that reduces amitotic division in polyploid giant cancer cells—Unrecognized players in tumorigenesis

  2020cites this paper
• CLEP_A_273566 1183..1203

  2020cites this paper
• Sex and Gender Disparities in Melanoma

  2020cites this paper
• Giants and monsters: Unexpected characters in the story of cancer recurrence.

  2020cites this paper
• Risk of melanoma in women with endometriosis: A Scottish national cohort study.

  2020cites this paper
• Effects of Exogenous Hormones and Reproductive Factors on Female Melanoma: A Meta-Analysis

  2020cites this paper
• Estrogen Receptors and Melanoma: A Review

  2019cites this paper
• Prise de traitements hormonaux et risque de mélanome cutané dans les cohortes prospectives E3N et EPIC

  2019cites this paper
• HRT: Einfluss auf Mortalität und Maligne Malignome

  2018cites this paper
• Hepatocyte‐generated 27‐hydroxycholesterol promotes the growth of melanoma by activation of estrogen receptor alpha

  2018cites this paper
• HRT: Einfluss auf Mortalität und Maligne Malignome

  2018cites this paper
• Polymorphisms in apoptosis-related genes in cutaneous melanoma prognosis: sex disparity

  2017cites this paper
• Menopausal hormone therapy and risk of melanoma: Do estrogens and progestins have a different role?

  2017cites this paper
• Oestrogen receptor expression in melanoma

  2017cites this paper
• The activation of the G protein-coupled estrogen receptor (GPER) inhibits the proliferation of mouse melanoma K1735-M2 cells.

  2017cites this paper
• Improved Survival in Male Melanoma Patients in the Era of Sentinel Node Biopsy

  2017cites this paper
• Einfluss einer Hormonersatztherapie auf das Risiko eines malignen Melanoms

  2017cites this paper
• Risk factors and outcomes of cutaneous melanoma in women less than 50 years of age.

  2016cites this paper
• Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity

  2016cites this paper
• Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility

  2016cites this paper
• Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance

  2016cites this paper
• Increased mortality for pregnancy‐associated melanoma: systematic review and meta‐analysis

  2015cites this paper
• The Differential Contribution of Behavior and Biology to Breslow Thickness and Melanoma Survival in Males Compared to Females

  2015influential citation
• Does Pregnancy After a Diagnosis of Melanoma Affect Prognosis? Systematic Review and Meta-analysis

  2015cites this paper
• The influence of pregnancy, parity, and sex on melanoma prognosis

  2015cites this paper
• Steroid hormone influence on melanomagenesis.

  2015cites this paper
• Rethinking tamoxifen in the management of melanoma: New answers for an old question.

  2015cites this paper
• Gender Differences in Melanoma Progression and Survival

  2014cites this paper
• The combination of the antiestrogen endoxifen with all-trans-retinoic acid has anti-proliferative and anti-migration effects on melanoma cells without inducing significant toxicity in non-neoplasic cells.

  2013cites this paper
• Therapeutics , Targets , and Chemical Biology 4-Hydroxytamoxifen Induces Autophagic Death through KRas Degradation

  2013cites this paper
• CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen.

  2013cites this paper
• Treatment strategies for melanoma: pharmacological and toxicological action mechanisms of combined therapies

  2013influential citation
• The Role of Chemotherapy for Metastatic Disease

  2013cites this paper
• Cisplatin and 4-hexylresorcinol synergise to decrease metastasis and increase survival rate in an oral mucosal melanoma xenograft model: a preliminary study

  2013cites this paper
• 4-Hydroxytamoxifen induces autophagic death through K-Ras degradation.

  2013cites this paper
• Chemotherapy in Metastatic Melanoma – Still Useful or Out of Date?

  2011cites this paper
• Long-Term Remissions in Metastatic Malignant Melanoma Following Chemotherapy and Tamoxifen Maintenance

  2011cites this paper